

REMARKS

Claims 3, 7 and 9-14 are pending in this application. The Examiner has required restriction to one of three groups:

Group I, claim(s) 3 and 7, drawn to a method for the treatment of epilepsy with a KCNQ 2/3 potassium channel opener;

Group II, claim(s) 9-13, drawn to a method for the preparation of a medicament with a KCNQ 2/3 potassium channel opener; or

Group III, claim(s) 11, drawn to a method of treating using retigabine.

In response to such restriction Applicants wish to proceed as follows.

Applicants provisionally elect, with traverse, Group III drawn to a method of treating using retigabine for proceeding with prosecution on the merits.

The examiner has suggested that the relevant claim(s) for Group III is Claim 11 but the applicant suggest that the correct claim is Claim 14 (i.e., there is a typographical error in the office action). By this restriction, it is applicants intent to request that the restriction be to a method of treating using retigabine.

Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to effect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,

*Bonnie L. Deppenbrock*  
Bonnie L. Deppenbrock  
Attorney for Applicants  
Registration No. 28,209

Date: 1 August, 2003  
GlaxoSmithKline  
Five Moore Drive, PO Box 13398  
Research Triangle Park, North Carolina 27709  
Telephone: (919) 483-1577  
Facsimile: (919) 483-7988